SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Danese S, Colombel JF, Reinisch W, et al. Review article: infliximab for Crohn's disease treatment — shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharm Ther. 2011; 33: 857869.
  • 2
    Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929936.
  • 3
    Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644653.
  • 4
    Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011; 306: 23312339.
  • 5
    Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 3035.
  • 6
    Lichtenstein GR, Feagen BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol. 2006; 4: 621630.
  • 7
    Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur J Gastroenterol Hepatol. 2011; 23: 11001110.
  • 8
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 13831395.
  • 9
    Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874881.
  • 10
    Kotylar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 3641.